RNAi therapy from Medicines Co., Alnylam cuts cholesterol by 54%, could compete with PCSK9 mAbs

The Medicines Co. announced data from a Phase III trial of inclisiran showing reductions in LDL-C that appear to be competitive with approved mAbs against PCSK9, but with a dosing advantage. Safety data from the study, which tested the RNAi therapeutic in patients with hypercholesterolemia

Read the full 455 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE